Price movement over the last 24 hours
Abeona Therapeutics Inc vs iShares Semiconductor ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while iShares Semiconductor ETF trades at $561.74. Which is the better fit depends on your goals.
| ABEO | SOXX | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $655.01 |
52-Week Low | $4.17 | $236.93 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SOXX, the iShares Semiconductor ETF, trades at $581.51, up 2.68% in the last 24 hours, with a neutral technical signal but bullish moving averages. The ETF has surged 93.3% year-to-date, driven by AI chip demand, yet faces recent volatility as hedge funds reduced exposure. Key support sits at $575, with resistance at $593. Financial ratios are not applicable for this ETF structure, which holds 30 U.S. semiconductor stocks.
Outlook remains cautiously optimistic given AI-driven growth, but risks include sector rotation, valuation concerns after sharp gains, and macroeconomic pressures. JPMorgan advises buying the dip, while Morgan Stanley notes potential pivot to hyperscalers. Investors should weigh strong thematic tailwinds against near-term volatility and high beta exposure.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →